Evidence map›Paper›PMID 34389634›Full record

ArticleLupus science & medicine2021

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.

Kristina K Deonaraine, Philip M Carlucci, Andrea Fava, Jessica Li, David Wofsy, Judith A James, Chaim Putterman, Betty Diamond, Anne Davidson, Derek M Fine and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. A population-scale atlas of blood and tissue in lupus nephritis.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 13 institutions in 1 country.

Kristina K DeonaraineDivision of Rheumatology, New York University Grossman School of Medicine, New York, NY, USA.
Philip M CarlucciDivision of Rheumatology, New York University Grossman School of Medicine, New York, NY, USA.
Andrea FavaDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Jessica LiDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
David WofsyRheumatology Division and Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, USA.
Judith A JamesArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Chaim PuttermanDivision of Rheumatology and Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
Betty DiamondCenter for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA.ORCID 0000-0002-3250-3804
Anne DavidsonCenter for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, USA.
Derek M FineDivision of Nephrology, Johns Hopkins University, Baltimore, MD, USA.
Jose Monroy-TrujilloDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Mohamed G AttaDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Kristin HaagDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Deepak A RaoDivision of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
William ApruzzeseDivision of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
H Michael BelmontDivision of Rheumatology, New York University Grossman School of Medicine, New York, NY, USA.
Peter M IzmirlyDivision of Rheumatology, New York University Grossman School of Medicine, New York, NY, USA.
Ming WuDepartment of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Sean ConneryDepartment of Internal Medicine, Paul L Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Fernanda Payan-SchoberDepartment of Internal Medicine, Paul L Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Richard A FurieDivision of Rheumatology, Northwell Health, Great Neck, NY, USA.
Celine C BerthierInternal Medicine, Department of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Maria Dall'EraRheumatology Division and Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, USA.
Kerry ChoNephrology Division, University of California San Francisco, San Francisco, CA, USA.
Diane L KamenDivision of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Kenneth KalunianUniversity of California San Diego School of Medicine, La Jolla, CA, USA.
Jennifer AnolikDepartment of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA.
Mariko IshimoriDivision of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael H WeismanDivision of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Accelerating Medicines Partnership RA/SLE network
Michelle A PetriDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA Jill.Buyon@nyulangone.org mpetri@jhmi.edu.ORCID 0000-0003-1441-5373
Jill P BuyonDivision of Rheumatology, New York University Grossman School of Medicine, New York, NY, USA Jill.Buyon@nyulangone.org mpetri@jhmi.edu.ORCID 0000-0002-3852-7129
Johns Hopkins University · USNew York University · USNorthwell Health · USUniversity of California, San Francisco · USBrigham and Women's Hospital · USCedars-Sinai Medical Center · USTexas Tech University · USAlbert Einstein College of Medicine · USMedical University of South Carolina · USOklahoma Medical Research Foundation · USUniversity of California San Diego · USUniversity of Michigan · USUniversity of Rochester Medical Center · US

Funding

Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
PEARL: Pathway Exploration and Analysis in Renal LupusUH2AR067688 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DIAMOND, BETTY, WOFSY, DAVID · 2014 to 2020
$9.0M
Tissue Acquisition Research GroupUM2AR067678 · NIAMS · STANFORD UNIVERSITY · PI HOLERS, VERNON MICHAEL, UTZ, PAUL JOSEPH · 2014 to 2020
$8.2M
Multi-Ethnic Translational Research Optimization (METRO) Lupus ConsortiumUH2AR067689 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUYON, JILL P, PUTTERMAN, CHAIM · 2014 to 2020
$6.3M
Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established DiseaseUH2AR067681 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2014 to 2020
$5.5M
Molecular and Cellular Dissection of Early Rheumatoid ArthritisUH2AR067694 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BRENNER, MICHAEL B., GREGERSEN, PETER K. · 2014 to 2020
$5.4M
RA-SLE Molecular Deconstruction Leadership CenterUH2AR067677 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2014 to 2020
$4.3M
Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic EfficacyR01AR075423 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PERLMAN, HARRIS R · 2019 to 2023
$3.0M
Cellular Dynamics at the Synovium-Bone interface in RAUH2AR067690 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2014 to 2020
$3.0M
Stanford Technology Accelerating Medicines Partnership CenterUH2AR067676 · NIAMS · STANFORD UNIVERSITY · PI ROBINSON, WILLIAM H, UTZ, PAUL JOSEPH · 2014 to 2020
$2.6M
NCATS NIH HHS UL1 TR003167NHGRI NIH HHS T32 HG002295NIAMS NIH HHS R01 AR069572NIAMS NIH HHS R01 AR075423NIAMS NIH HHS UH2 AR067676NIAMS NIH HHS UH2 AR067677NIAMS NIH HHS UH2 AR067679NIAMS NIH HHS UH2 AR067681NIAMS NIH HHS UH2 AR067685NIAMS NIH HHS UH2 AR067688NIAMS NIH HHS UH2 AR067689NIAMS NIH HHS UH2 AR067690NIAMS NIH HHS UH2 AR067691NIAMS NIH HHS UH2 AR067694NIAMS NIH HHS UM2 AR067678
6 · The paper itself

Abstract

objectivesIn lupus nephritis the pathological diagnosis from tissue retrieved during kidney biopsy drives treatment and management. Despite recent approval of new drugs, complete remission rates remain well under aspirational levels, necessitating identification of new therapeutic targets by greater dissection of the pathways to tissue inflammation and injury. This study assessed the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership, a consortium formed to molecularly deconstruct nephritis.

methods475 patients with SLE across 15 clinical sites in the USA consented to obtain tissue for research purposes during a clinically indicated kidney biopsy. Adverse events (AEs) were documented for 30 days following the procedure and were determined to be related or unrelated by all site investigators. Serious AEs were defined according to the National Institutes of Health reporting guidelines.

results34 patients (7.2%) experienced a procedure-related AE: 30 with haematoma, 2 with jets, 1 with pain and 1 with an arteriovenous fistula. Eighteen (3.8%) experienced a serious AE requiring hospitalisation; four patients (0.8%) required a blood transfusion related to the kidney biopsy. At one site where the number of cores retrieved during the biopsy was recorded, the mean was 3.4 for those who experienced a related AE (n=9) and 3.07 for those who did not experience any AE (n=140). All related AEs resolved.

conclusionsProcurement of research tissue should be considered feasible, accompanied by a complication risk likely no greater than that incurred for standard clinical purposes. In the quest for targeted treatments personalised based on molecular findings, enhanced diagnostics beyond histology will likely be required.

Indexed as

Arteriovenous FistulaLupus NephritisBiopsyHematomaHumansKidneyUnited Statesautoimmunitylupus erythematosuslupus nephritissystemic

Identifiers

PMID34389634
PMCPMC8354250
OpenAlexW3191882459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.